From Earlier: Inovio Pharmaceuticals Receives Defense Department Funding for Bioterrorism-Related Synthetic Vaccine Program
Inovio Pharmaceuticals, Inc. (NYSE: INO) announced today it has received a U.S. Department of Defense Small Business Innovation Research Grant to advance the development of a low-cost, non-invasive surface electroporation delivery device and test its utility in combination with Inovio's novel synthetic DNA vaccines against viruses with bioterrorism potential, including hanta, puumala, arenavirus and pandemic influenza.
This project is a continuation of a first-stage DOD grant in 2011 that initiated Inovio's development of this skin delivery system.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.